PARTEST: Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens

Sponsor

Orion Corporation, Orion Pharma (Industry)

Overall Status

Completed

CT.gov ID

NCT01296464

Collaborator

(none)

Enrollment

Locations

Arms

4.9

Duration (Months)

5.4

Patients Per Site

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective is to assess the effect of a single dose of two experimental levodopa/carbidopa/entacapone (L/C/E) treatment regimens versus standard L/C/E treatment regimen in Parkinson's disease (PD) patients with end-of-dose motor fluctuations in terms of duration of motor response after the first morning dose of levodopa. The secondary objective is to evaluate the safety of the L/C/E treatment regimens in patients with PD.

Condition or Disease	Intervention/Treatment	Phase
Parkinson's Disease	Drug: Carbidopa	Phase 2

Detailed Description

This is a randomised, double-blind, 3-period crossover study comparing the effects of a single dose of two L/C/E treatment regimens (A and B) and standard L/C/E treatment regimen (Stalevo) on the duration of motor response in PD patients with wearing-off symptoms after the first morning dose of levodopa.

The study consists of a screening visit, 3 treatment visits and an end-of-study visit. Within 14 days of the screening visit, the patients will receive a single morning dose of study drug (either of the two L/C/E treatment regimens) or Stalevo. The order of the 3 treatment periods will be randomised according to a crossover design and the duration of each period is 2 days, followed by a wash-out period (1-9 days) during which the patients will be on their individual standard PD treatment.

Before each study day, patients will arrive at the study centre in the previous evening. The patients' own standard PD treatments will be discontinued at the latest by 22:00 to be continued after completion of the motor part (part III) of the Unified Parkinson's Disease Rating Scale (UPDRS III) next day. After completion of the UPDRS III, patients will return to their own standard PD treatments. Duration of the study will be 2 to 7 weeks per patient, depending on the length of the screening and wash-out periods.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

27 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Prevention

Official Title:

Duration of Motor Response After Administration of Experimental Levodopa/Carbidopa/Entacapone Treatment Regimens Compared to Standard Treatment (Stalevo®);a Randomised,Double-blind,Crossover,Multicentre,Single Dose Study in Patients With Parkinson?s Disease and Wearing-off Symptoms

Study Start Date :

Feb 1, 2011

Actual Primary Completion Date :

Jul 1, 2011

Actual Study Completion Date :

Jul 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Stalevo levodopa/carbidopa/entacapone	Drug: Carbidopa Capsules
Placebo Comparator: Placebo	Drug: Carbidopa Capsules

Arm

Intervention/Treatment

Experimental: Stalevo

levodopa/carbidopa/entacapone

Drug: Carbidopa

Capsules

Placebo Comparator: Placebo

Drug: Carbidopa

Capsules

Outcome Measures

Primary Outcome Measures

Duration of motor response by UPDRS III [20 minute intervals]
Statistical method for the primary comparison will be analysis of variance (ANOVA) with the following grouping factors: treatment, sequence, subject, and period. Differences between Stalevo and treatment regimen A will be evaluated using orthogonal contrasts with 5% significance level.

Eligibility Criteria

Criteria

Ages Eligible for Study:

30 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Written informed consent (IC) obtained.
Male or female patients with idiopathic PD according to the United Kingdom brain bank criteria with end-of-dose motor fluctuations
Hoehn and Yahr stage 2-4 performed during the "ON" state.
Duration of response between 1.5 and 4 hours (based on medical history) to the patient's first morning dose of levodopa/dopa decarboxylase inhibitor (DDCI) with or without entacapone.
Treatment with 3-8 daily doses of levodopa/DDCI with or without entacapone with a total daily levodopa dose in the range of 300-1200 mg. One evening dose of controlled-release formulation of levodopa/DDCI is allowed provided that it is included in the total of 3-8 daily doses of levodopa/DDCI mentioned above.
Unchanged levodopa/DDCI with or without entacapone and other antiparkinsonian medication(dopamine agonists, monoamine oxidase [MAO] B inhibitor, amantadine and/or anticholinergics with approved doses), if any, for at least 6 weeks prior to the screening visit.
Age of 30 years or above

Exclusion Criteria:

Secondary or atypical parkinsonism.
Use of tolcapone within 6 weeks prior to the first treatment period.
Previous tolerability problems with entacapone or tolcapone.
Concomitant treatment with apomorphine, MAO-A inhibitors or nonselective MAO inhibitors.
Concomitant treatment with drugs having antidopaminergic action including alpha-methyldopa, reserpine and antipsychotic drugs (also D2 receptor blocking antiemetics except domperidone). As an exception, an evening dose of an atypical antipsychotic is allowed.
Use of any iron preparations.
Intensity of dyskinesias which would, in the opinion of the investigator, interfere with the interpretation of motor part (part III of the Unified Parkinson's Disease Rating Scale (UPDRS III) scoring during the levodopa challenge test.
Currently active hallucinations.
Severe orthostatic hypotension as judged by the investigator.
Mini-Mental State Examination (MMSE) score < 26
History of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis.
Past or current treatment with deep brain stimulation (DBS) or other surgical treatment for PD.
Treatment with levodopa or dopamine agonist infusion or injection
Active malignancy, narrow-angle glaucoma or pheochromocytoma.
Clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
Alanine aminotransferase or aspartate aminotransferase > upper limit of normal at screening.
Any other abnormal value of laboratory, vital signs or electrocardiogra (ECG) which would in the opinion of the investigator interfere with the interpretation of the study results or cause health risk for the subject if he/she takes part into the study.
Female patients of childbearing potential (i.e. menstruating or less than 2 years postmenopausal) if they are not using proper contraception (hormonal contraception, intrauterine device [IUD] or surgical sterilisation, spermicidal foam in conjunction with condom on male partner).
Patients with pre-planned elective surgery.
Known hypersensitivity to active substances or to any of the excipients of the study drugs.
Participation in a drug study within 60 days prior to entry to this study.
Any other condition that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Kanta-Hämeen keskussairaala	Hämeenlinna	Finland	13530
2	ODL Terveys Oy (ODL)	Oulu	Finland	90100
3	Porin Lääkäritalo	Pori	Finland	28100
4	Länssjukhuset Ryhov, Medicin/Neurologmottagningen	Jönköping	Sweden	SE-55185
5	Karolinska Universitetssjukhuset Solna, Neurologkliniken	Stockholm	Sweden	SE-171 76